The Expression Profile of SLC22A6 and SLC22A8 genes in Kidney Renal clear Cell Carcinoma and Their Association with Clinical Outcomes
Cancer Genetics and Therapeutics
-
Primary Categories:
- Cancer
-
Secondary Categories:
- Cancer
Introduction:
Kidney renal clear cell carcinoma (KIRC) is the most prevalent subtype of renal cell carcinoma (RCC) with poor prognosis and a high mortality rate. Organic anion transporters (OATs), encoded by the SLC22 gene family, mainly interacting with organic anionic molecules, are located on either basolateral membrane or apical membrane of the proximal tubule cells and are responsible for the excretion of numerous endogenous and exogenous substances. OAT1 (SLC22A6 gene), and OAT3 (SLC22A8 gene) are renal transporters highly expressed in the kidney. We aimed to systematically analyze SLC22A6 and SLC22A8 expression and their prognostic role in KIRC using various open databases.
Methods:
Comparison of KIRC and matched normal tissue gene expression was performed with the UALCAN and GEPIA online graphical user interfaces. The promoter methylation levels were examined by UALCAN. Correlation between SLC22A6 and SLC22A8 gene expression and patient survival was evaluated with OncoLnc. SLC22A6 and SLC22A8 genetic alterations in KIRC were also explored using cBioPortal.
Results:
Expression of SLC22A6 and SLC22A8 is significantly down-regulated in the clinic-pathological characteristics (cancer stages, tumor grade and nodal metastasis status) examined in KIRC patients compared to normal counterparts. SLC22A6 and SLC22A8 promoter methylation level in KIRC was lower than that in normal kidney tissue. Clinically, low expression of SLC22A6 and SLC22A8 is correlated with shorter overall survival in KIRC patients, with a log-rank p-value of 0.0000005 and 0.00008, respectively. Analysis of the TCGA kidney renal clear cell carcinoma dataset (TCGA's Pan-Cancer Atlas) revealed a low mutation frequency in KIRC for SLC22A6 (1.42%) and SLC22A8 (1.14%).
Conclusion:
SLC22A6 and SLC22A8 are highly expressed in the kidney and play key roles in kidney diseases. In KIRC patients, downregulation of SLC22A6 and SLC22A8expression has been observed. SLC22A6 and SLC22A8 expression levels may also serve as prognostic predictive markers in KIRC patients.
Kidney renal clear cell carcinoma (KIRC) is the most prevalent subtype of renal cell carcinoma (RCC) with poor prognosis and a high mortality rate. Organic anion transporters (OATs), encoded by the SLC22 gene family, mainly interacting with organic anionic molecules, are located on either basolateral membrane or apical membrane of the proximal tubule cells and are responsible for the excretion of numerous endogenous and exogenous substances. OAT1 (SLC22A6 gene), and OAT3 (SLC22A8 gene) are renal transporters highly expressed in the kidney. We aimed to systematically analyze SLC22A6 and SLC22A8 expression and their prognostic role in KIRC using various open databases.
Methods:
Comparison of KIRC and matched normal tissue gene expression was performed with the UALCAN and GEPIA online graphical user interfaces. The promoter methylation levels were examined by UALCAN. Correlation between SLC22A6 and SLC22A8 gene expression and patient survival was evaluated with OncoLnc. SLC22A6 and SLC22A8 genetic alterations in KIRC were also explored using cBioPortal.
Results:
Expression of SLC22A6 and SLC22A8 is significantly down-regulated in the clinic-pathological characteristics (cancer stages, tumor grade and nodal metastasis status) examined in KIRC patients compared to normal counterparts. SLC22A6 and SLC22A8 promoter methylation level in KIRC was lower than that in normal kidney tissue. Clinically, low expression of SLC22A6 and SLC22A8 is correlated with shorter overall survival in KIRC patients, with a log-rank p-value of 0.0000005 and 0.00008, respectively. Analysis of the TCGA kidney renal clear cell carcinoma dataset (TCGA's Pan-Cancer Atlas) revealed a low mutation frequency in KIRC for SLC22A6 (1.42%) and SLC22A8 (1.14%).
Conclusion:
SLC22A6 and SLC22A8 are highly expressed in the kidney and play key roles in kidney diseases. In KIRC patients, downregulation of SLC22A6 and SLC22A8expression has been observed. SLC22A6 and SLC22A8 expression levels may also serve as prognostic predictive markers in KIRC patients.